The Latest Cardiac and Vascular News
Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that its common stock will continue trading on The Nasdaq Capital Market (“Nasdaq”).
FORT MILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at three upcoming conferences through April 2, 2025.
HONG KONG, March 26, 2025 /PRNewswire/ — Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year ended December 31, 2024 (“the Year”) on March 25,…
NEW YORK–(BUSINESS WIRE)–Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA). This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI […]
CHICAGO–(BUSINESS WIRE)–Cleerly, a leader in AI imaging technology, is proud to support the American College of Cardiology’s (ACC) Chicago Community Health Fair. This event will take place on Tuesday, March 25, from 3-7 p.m. CT at The Salvation Army Ray & Joan Kroc Corps Community Center. Heart disease is the leading cause of death […]
Funding to accelerate development of next-generation intravascular ultrasound platform and support FDA clearance for U.S. market launch SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B financing with new […]
SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International. Twelve-month results from the randomized arm of the WAVE trial are scheduled for presentation at the Society of Interventional Radiology’s 50th Annual Scientific Meeting in Nashville, TN. The podium presentation is scheduled for March 30, 2025, during the late-breaking trials session.
Twenty AEDs donated to communities across the country to protect young hearts from sudden cardiac arrest FRANKLIN, Tenn., March 25, 2025 /PRNewswire/ — Coro Medical, a leader in life-saving medical devices, is proud to announce a new partnership with Simon’s Heart as part of its…
BEIJING, March 25, 2025 /PRNewswire/ — Jenscare Scientific Co., Ltd. (“Jenscare” or the “Company”) (HKEX: 9877), an innovative medical device company with TTVR breakthroughs and is entering commercialization stage for its TAVR (AR) product, released its annual results for year ended…
AI-enabled cardiovascular ultrasound platform
AI-enabled cardiovascular ultrasound platform
Lumiguide navigation wire
Azurion
Azurion with 3d treatment view
Spectral CT7500 for RT
March 25, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that in 2024 it was the leading applicant in the field of medical technology at the European Patent Office (EPO), filing 594 Medtech patent applications. This achievement underscores the company’s ongoing dedication to transforming healthcare delivery by integrating informatics and AI to improve workflows, enhance the quality of care, and lower costs of care per patient.The innovations by Philips, which can boast 134 years of innovation history with its research and development programs around the globe, improved the health and well-being of nearly 2 billion people in 2024, keeping it on track towards its target of 2.5 billion lives improved in 2030.Roy Jakobs, CEO of Royal Philips said: “For more than 130 years, Philips has been at the forefront of innovations improving people’s lives. The 2024 European patent rankings show how we continue to innovate in the hospital and the home – helping to deliver better care for more people. To continue driving greater impact, we have shifted our innovation closer to customers. We want to help healthcare professionals improve patient care and empower people everywhere to take care of their health and well-being.” As informatics and AI increasingly create value for healthcare both at the hospital as well as at home, approximately half of the company’s R&D investments are focused on these technologies. Some of the informatics and AI-powered innovations that Philips launched in 2024 include: The new Azurion image-guided therapy system with advanced informatics to enhance minimally invasive diagnosis and treatment of stroke and other neurovascular patients.FDA-cleared AI tools integrated into the EPIQ CVx and Affiniti CVx ultrasound system to advance cardiovascular imaging and increase automation and productivity, reinforcing Philips’ #1 global position in cardiovascular ultrasound. The new Philips Spectral CT 7500 RT, enabling personalized radiation therapy planning to deliver better care to more cancer patients.FDA approval for the LumiGuide Navigation Wire, which uses fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery. In total, Philips contributed 1,231 European patent applications across various domains, the most of any Dutch company and continuing the company’s legacy as one of the top applicants since the EPO started publishing the rankings in 2004.Further illustrating Philips’ innovation leadership is the company’s recent inclusion in the Clarivate Top 100 Global Innovators 2025, marking the company’s 12th consecutive inclusion in this major assessment of global innovators.Philips invested approximately EUR 1.7 billion in research and development in 2024 to help drive better care for more people. At more than 9% of sales, this is well above the industry average. The company’s extensive intellectual property portfolio includes 50,500 patent rights, 30,500 trademarks, 150,000 design rights, and 3,200 domain names. For further information, please contact: Elco van GroningenPhilips Global External RelationsTel.: +31 6 8103 9584E-mail: media@philips.com About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
AI-enabled cardiovascular ultrasound platform
AI-enabled cardiovascular ultrasound platform
Lumiguide navigation wire
Azurion
Azurion with 3d treatment view
Spectral CT7500 for RT
